NASDAQ:TYRA Tyra Biosciences (TYRA) Stock Price, News & Analysis $20.11 +0.39 (+1.95%) Closing price 03:58 PM EasternExtended Trading$20.09 -0.02 (-0.12%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Tyra Biosciences Stock (NASDAQ:TYRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tyra Biosciences alerts:Sign Up Key Stats Today's Range$19.48▼$20.4450-Day Range$18.52▼$25.7352-Week Range$18.25▼$40.65Volume256,513 shsAverage Volume880,285 shsMarket Capitalization$1.39 billionP/E RatioN/ADividend YieldN/APrice Target$47.50Consensus RatingModerate Buy Company Overview Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers. These are investigational candidates and are not approved for commercial use. Founded in 2018 and based in Carlsbad, California, Tyra conducts drug discovery and clinical development. Todd Harris, a company co-founder, serves as its chief executive officer.AI Generated. May Contain Errors. Read More Tyra Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreTYRA MarketRank™: 2.611940298505 of 5 starsTyra Biosciences scored higher than 52% of companies evaluated by MarketBeat, and ranked 499th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingTyra Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 2 strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTyra Biosciences has a consensus price target of $47.50, representing about 137.0% upside from its current price of $20.05.Amount of Analyst CoverageTyra Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tyra Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tyra Biosciences are expected to decrease in the coming year, from ($2.78) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tyra Biosciences is -7.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tyra Biosciences is -7.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTyra Biosciences has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.96% of the float of Tyra Biosciences has been sold short.Short Interest Ratio / Days to CoverTyra Biosciences has a short interest ratio ("days to cover") of 15.28, which indicates bearish sentiment.Change versus previous monthShort interest in Tyra Biosciences has recently increased by 4.28%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTyra Biosciences does not currently pay a dividend.Dividend GrowthTyra Biosciences does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment-0.22 News SentimentTyra Biosciences has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Tyra Biosciences this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Tyra Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $20,004.00 in company stock, which represents 0.0014% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Tyra Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,004.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.50% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tyra Biosciences' insider trading history. Receive TYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TYRA Stock News HeadlinesHC Wainwright Cuts Earnings Estimates for Tyra BiosciencesNovember 15, 2026 | americanbankingnews.comTyra Biosciences, Inc. (TYRA) - What Are Brokerages Thinking About This Stock?November 14, 2026 | americanbankingnews.comWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 20 at 1:00 AM | Porter & Company (Ad)Tyra Biosciences (NASDAQ:TYRA) Stock Gets Price Target Reduction from HC WainwrightNovember 14, 2026 | americanbankingnews.comTyra Biosciences (NASDAQ:TYRA) Price Target Raised to $57.00November 14, 2026 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: Claritev (CTEV), Tyra Bioscience (TYRA)November 13, 2026 | theglobeandmail.comCertain Restricted Stock Units of Tyra Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 13-NOV-2026.November 12, 2026 | marketscreener.comMTyra Biosciences (NASDAQ:TYRA) Stock Breaks Below Fifty Day Moving Average on Disappointing EarningsNovember 12, 2026 | americanbankingnews.comSee More Headlines TYRA Stock Analysis - Frequently Asked Questions How have TYRA shares performed this year? Tyra Biosciences' stock was trading at $26.29 at the start of the year. Since then, TYRA shares have decreased by 23.8% and is now trading at $20.0460. How were Tyra Biosciences' earnings last quarter? Tyra Biosciences, Inc. (NASDAQ:TYRA) posted its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.67) by $0.07. When did Tyra Biosciences IPO? Tyra Biosciences (TYRA) raised $162 million in an initial public offering on the week of September 13th 2021. The company issued 10,800,000 shares at $14.00-$16.00 per share. Who are Tyra Biosciences' major shareholders? Top institutional investors of Tyra Biosciences include State Street Corp (3.35%), Integral Health Asset Management LLC (0.66%), Goldman Sachs Group Inc. (0.66%) and Soleus Capital Management L.P. (0.64%). Insiders that own company stock include Robert J More, Todd Harris, Nina S Kjellson, Daniel Bensen, Gilla Kaplan, Alan Fuhrman and Rehan Verjee. View institutional ownership trends. How do I buy shares of Tyra Biosciences? Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tyra Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tyra Biosciences investors own include NVIDIA (NVDA), Pyxis Oncology (PYXS), Tenaya Therapeutics (TNYA), Micron Technology (MU), Dutch Bros (BROS), CAVA Group (CAVA) and Broadcom (AVGO). Company Calendar Last Earnings11/10/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TYRA's financial health is in the Red zone, according to TradeSmith. TYRA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TYRA CIK1863127 Webwww.tyra.bio Phone619-728-4760FaxN/AEmployees87Year Founded2018Price Target and Rating Average Price Target for Tyra Biosciences$47.50 High Price Target$57.00 Low Price Target$27.00 Potential Upside/Downside+137.4%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$119.95 million Net MarginsN/A Pretax MarginN/A Return on Equity-40.12% Return on Assets-37.62% Debt Debt-to-Equity RatioN/A Current Ratio23.93 Quick Ratio23.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.03 per share Price / Book1.99Miscellaneous Outstanding Shares69,080,000Free Float60,448,000Market Cap$1.38 billion OptionableOptionable Beta0.65 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:TYRA) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredBlack Friday Special: Buy These Stocks Before Nov. 30thKeith Kaplan's firm has invested $17 million in its own AI research and tools, and 180,000 people worldwide no...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyra Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tyra Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.